Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Endo determined to discontinue its registries and the CURVE registry enrollment has been closed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational study, meaning participants will not receive any investigational treatment as part of this study.
Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Receiving Each Treatment Type for PD | Up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score | Up to 12 months | |
| Change from Baseline in International Index of Erectile Function (IIEF) Score | Up to 12 months | |
Not provided
Key Inclusion Criteria:
Key Exclusion criteria:
Not provided
Not provided
Not provided
Participants with a confirmed diagnosis of PD will be enrolled in the United States.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Information | Endo USA Inc., a Keenova Therapeutics Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Endo Pharmaceuticals Clinical Site 2 | San Diego | California | 92120 | United States | ||
| Endo Pharmaceuticals Clinical Site 3 |
Not provided
| ID | Term |
|---|---|
| D010411 | Penile Induration |
| ID | Term |
|---|---|
| D010409 | Penile Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score |
| Up to 12 months |
| Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score | Up to 12 months |
| Participant Satisfaction Questionnaire | Up to 12 months |
| Number of Participants Receiving Post-Procedural Care by the Treating Physician | Up to 12 months |
| Miami |
| Florida |
| 33136 |
| United States |
| Endo Pharmaceuticals Clinical Site 6 | Greenwood | Indiana | 46143 | United States |
| Endo Pharmaceuticals Clinical Site 5 | Lansing | Michigan | 48912 | United States |
| Endo Pharmaceuticals Clinical Site 7 | Gahanna | Ohio | 43230 | United States |
| Endo Pharmaceuticals Clinical Site 4 | Houston | Texas | 77030 | United States |
| Endo Pharmaceuticals Clinical Site 1 | Orem | Utah | 84057 | United States |
| D052801 |
| Male Urogenital Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |